New lenses show promise for sustained glaucoma treatment

Article

Researchers at University of California, Los Angeles, USA, have developed a new delivery system for treating patients with glaucoma. They have combined nanodiamonds - a by-product of conventional mining and refining processes - with timolol maleate into contact lenses that deliver sustained doses.

Researchers at University of California, Los Angeles, USA, have developed a new delivery system for treating patients with glaucoma. They have combined nanodiamonds - a by-product of conventional mining and refining processes - with timolol maleate into contact lenses that deliver sustained doses.

This new technology has shown great promise for sustained glaucoma treatment. When applied to nanodiamond-embedded lenses, timolol is released when it comes into contact with lysozyme, an enzyme found in tears.

The study was lead by Dr Dean Ho, PhD, MS, professor of oral biology and medicine and co-director of the Jane and Jerry Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry, and supported by the National Cancer Institute, the National Science Foundation, the Wallace H. Coulter Foundation, The V Foundation for Cancer Research, the Society for Laboratory Automation and Screening, Beckman Coulter Life Sciences, and Singapore's Agency for Science, Technology and Research.

Previously, researchers at UCLA had shown that nanodiamonds could potentially be used to treat other diseases and disorders, including cancer and osteonecrosis of the jaw.

"In addition to nanodiamonds' promise as triggered drug-delivery agents for eye diseases, they can also make the contact lenses more durable during the course of insertion, use and removal, and more comfortable to wear," said Dr Ho, who is also a professor of bioengineering and a member of the Jonsson Comprehensive Cancer Center and the California NanoSystems Institute.

Nanodiamonds - approximately five nanometres in diameter - are small ball-like shapes and can be used to bind a broad spectrum of drug compounds, allowing them to be released over long periods of time.

"Delivering timolol through exposure to tears may prevent premature drug release when the contact lenses are in storage and may serve as a smarter route toward drug delivery from a contact lens," said Kangyi Zhang, co-first author of the study and a graduate student in Dr Ho's lab.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.